This article explores multiplexing applications in biopharma and highlights key assay development factors to consider.

TD Cowen 46th Annual Health Care Conference March 2, 2026 9:50 AM ESTCompany ParticipantsAdam Lenkowsky - Executive ...

From today, thousands more Australians living with advanced and rare cancers will have access to affordable immunotherapy treatment options through ...

When you get as many things going wrong as there are right now, you do not think about opportunity; you think about safety. I ...

Bristol Myers Squibb (BMY) ended the recent trading session at $62.37, demonstrating a +2.08% change from the preceding day's closing price. The stock outpaced the S&P 500's daily loss of 0.43% ...

Mumbai: Govt and govt aided institutions will soon be brought under the purview of the Maharashtra Unaided Private ...

Last week, the FDA made its one pivotal trial policy official, sparking myriad questions from industry leaders, including ...

If you are planning your distance education journey, check out the list of UGC-approved distance education courses and ...

Rare disease drug developers struggle to survive in a biopharma investment market that prioritizes large patient populations.

The education platform for indie authors launches a phased rollout of new courses each week on a redesigned campus ...

Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end cash and restricted cash position was ...

Starting biologic therapy at diagnosis, rather than escalating later, may significantly reduce complications and ...